

Tissue Therapies Limited (trading as Factor Therapeutics) (ASX Code: TIS)
Additional placement details

In accordance with Listing Rule 3.10.5A, Tissue Therapies Limited (trading as Factor Therapeutics) (**Factor**) advises as follows in relation to the placement announced this morning:

- 1 The dilution to existing shareholders as a result of the placement is as follows:

	Share Details	Dilution
Number of shares on issue prior to the placement	302,878,835	
Placement under listing rule 7.1	45,431,825	15%
Placement under listing rule 7.1A	30,287,883	10%
Number of shares on issue following the placement	378,598,543	
		25%

- 2 Factor issued shares to sophisticated and institutional investors as it was considered to be a more efficient mechanism for raising the Company's immediate capital needs. The placement did not expose Factor to the market volatility that may have been experienced over a more protracted capital raising process. As announced today, Factor is also intending to conduct a non-renounceable entitlement offer to allow existing eligible shareholders to participate in the overall capital raising process.
- 3 The lead manager, Taylor Collison Limited, is entitled to a management fee of 2% and a selling fee of 4% of the gross proceeds raised under the placement, less any amount raised from participants that are currently shareholders of Factor.

Corporate Contact

Dr. Christian P. Behrenbruch
Executive Director
Tissue Therapies Limited, trading as Factor Therapeutics
Tel: +61 7 3334 3900
Email: c.behrenbruch@factor-therapeutics.com

About Factor Therapeutics

Tissue Therapies Limited (trading as Factor Therapeutics) is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. Factor Therapeutics is commercialising VF-001 (previously denoted VitroGro® ECM), a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The business owns various patent families related to wound healing and other therapeutic uses. The Company's shares are traded on the Australian, Berlin and Frankfurt stock exchanges. For more information, please visit www.factor-therapeutics.com

Important information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the 'US Securities Act'), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. This document may not be distributed or released in the United States.